Sauchelli S, Rogers PJ, Fry G, Hamilton-Shield JP. Preference for high carbohydrate foods does not change for children and adolescents in insulin-induced hypoglycemia. BMJ Open Diabetes Res Care. 2022 Nov 8;10(6). doi: 10.1136/bmjdrc-2022-003065
Sauchelli S, Bradley J, England C, Searle A, Whitmarsh A. Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002162. doi: 10.1136/bmjdrc-2021-002162
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Schwab P, Saundankar V, Bouchard J, Wintfeld N, Suehs B, Moretz C, Allen E, DeLuzio A. Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs. BMJ Open Diabetes Res Care. 2016 Feb 18;4(1):e000099. doi: 10.1136/bmjdrc-2015-000099
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.